[SR-Users] Phase III clinical trials of Kamailio DMQ

For immediate release: GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication. In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms. The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource. The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population." As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort: "Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity." Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms. Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch. Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives." Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial. "The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method." Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously. -- Alex Balashov | Principal | Evariste Systems LLC Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/